Saluda Medical Inc · ASX:SLD
Saluda Medical — Investor Presentation (December 2025)
12 slides from Saluda Medical's investor presentation, Dec 5, 2025
Slide 1: Saluda Medical Update
For personal use only Saluda Medical Update December 5th, 2025 Weare on a Mission to Transform Patients’ Lives with Revolutionary Neural-Sensing Technology
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer THIS DOCUMENT AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIB
Slide 3: Board and Senior Management
Board and Senior Management Highly experienced and a proven track record of delivering shareholder value LEADERSHIP TEAM For personal use only Barry Regan Jim Erickson Mike Mathias Aidan O’Sullivan President & Chief Chief Financial Officer Chief Commercial Officer Chief Operations Officer Executive
Slide 4: Board and Senior Management (cont.)
Board and Senior Management (cont.) Highly experienced and a proven track record of delivering shareholder value BOARD MEMBERS For personal use only BOARD MEMBERS Doug Godshall Robert Palmisano Catherine Livingstone Dr Geoff Brooke Quentin Blackford Rob Faulkner Chairman Director Director Director D
Slide 5: Company Overview
Company Overview Saluda is a revolutionary closed-loop, neural-sensing and modulation platform technology For personal use only • Founded in Sydney, Australia (2010) EARLY COMMERCIAL RESULTS • Saluda founder was an ex-CTO of Cochlear. Technology Developed over 10 years. • Initial application in Spin
Slide 6: Spinal Cord Stimulation (SCS) is an Established Market
Spinal Cord Stimulation (SCS) is an Established Market SCS represents a substantial opportunity which remains significantly underserved For personal use only Annual cost of chronic pain in ~24% of American Adults2 US exceed costs of heart disease, cancer and diabetes1 have chronic pain ~6% Estimated
Slide 7: Traditional Fixed Dose SCS for Chronic Pain
Traditional Fixed Dose SCS for Chronic Pain Well-established therapy for the treatment of chronic neurological pain For personal use only 4 Patient adjusts stimulation with remote control 30+ times per day1 SCS leads are implanted near the spinal cord to deliver electrical 3 stimulation from an impl
Slide 8: Saluda Medical | Personalised, Closed-Loop Technology
Saluda Medical | Personalised, Closed-Loop Technology Saluda Medical’s three major breakthroughs represent a paradigm shift in SCS therapy For personal use only 1 Enables personalised closed- loop SCS to deliver life changing Measures the nerve’s response improvements in pain to stimulation manageme
Slide 9: Breakthrough Clinical Data, Patient Outcomes & Therapy Burden
Breakthrough Clinical Data, Patient Outcomes & Therapy Burden Backed by the world’s only double-blinded trial in SCS conducted over 3 years For personal use only Closed-loop system reads, measures OUTCOME HIGHLIGHTS and responds to patient-specific needs Ensures accurate physiologic dosing in real-t
Slide 10: Market Adoption
1 Market Adoption Saluda’s Evoke device is gaining market share with positive momentum since launch For personal use only REVENUE PROFILE(US$M)1 COMMENTARY With strong growth in key metrics, Saluda is well positioned to continue its expansion over the forecast period. 54% CAGR 75 $21.2 US Key Growth
Slide 11: Investment Highlights
Investment Highlights Saluda is a revolutionary closed-loop, neural Evoke – a highly differentiated Spinal Cord Stimulation (SCS) device, with ~US$82M (~A$126M)1 revenue forecasted in FY26 → approved and sold in key global markets (U.S, AUS and EU) sensing and modulation For personal use only platfo
Slide 12: Therapy as Dynamic as Life.
For personal use only EVERYTHING CHANGES. THIS CHANGES EVERYTHING. Therapy as Dynamic as Life.
Saluda Medical — Investor Presentation (December 2025) on 6ix